Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Screws | 3 | 2016 | 31 | 1.460 |
Why?
|
| Lower Extremity Deformities, Congenital | 2 | 2014 | 2 | 0.950 |
Why?
|
| Guided Tissue Regeneration | 2 | 2014 | 4 | 0.950 |
Why?
|
| Bone Plates | 2 | 2014 | 16 | 0.940 |
Why?
|
| Bone Regeneration | 2 | 2014 | 69 | 0.900 |
Why?
|
| Lower Extremity | 1 | 2022 | 88 | 0.800 |
Why?
|
| Models, Biological | 2 | 2014 | 723 | 0.740 |
Why?
|
| Scoliosis | 2 | 2016 | 60 | 0.630 |
Why?
|
| Spinal Fusion | 2 | 2016 | 70 | 0.620 |
Why?
|
| External Fixators | 2 | 2014 | 9 | 0.610 |
Why?
|
| Ilium | 1 | 2016 | 8 | 0.530 |
Why?
|
| Sacrum | 1 | 2016 | 19 | 0.520 |
Why?
|
| Cerebral Palsy | 1 | 2016 | 40 | 0.510 |
Why?
|
| Fractures, Malunited | 1 | 2014 | 1 | 0.490 |
Why?
|
| Fractures, Ununited | 1 | 2014 | 3 | 0.490 |
Why?
|
| Tibial Fractures | 1 | 2014 | 32 | 0.480 |
Why?
|
| Osteogenesis, Distraction | 1 | 2014 | 78 | 0.470 |
Why?
|
| Glomus Tumor | 1 | 2013 | 2 | 0.460 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 57 | 0.430 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 202 | 0.310 |
Why?
|
| Lymph Nodes | 1 | 2009 | 263 | 0.280 |
Why?
|
| Arm | 1 | 2006 | 47 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 193 | 0.280 |
Why?
|
| Stomach Neoplasms | 1 | 2009 | 179 | 0.260 |
Why?
|
| Radiography | 3 | 2016 | 491 | 0.260 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 328 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 397 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 613 | 0.250 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 905 | 0.230 |
Why?
|
| Databases, Factual | 2 | 2016 | 657 | 0.200 |
Why?
|
| Humans | 13 | 2022 | 50208 | 0.200 |
Why?
|
| Analysis of Variance | 2 | 2016 | 564 | 0.190 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2021 | 8 | 0.190 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 765 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2016 | 5155 | 0.170 |
Why?
|
| Athletic Injuries | 1 | 2021 | 190 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 454 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2014 | 1422 | 0.150 |
Why?
|
| Prosthesis Design | 2 | 2016 | 237 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2009 | 666 | 0.150 |
Why?
|
| Child | 4 | 2021 | 6851 | 0.140 |
Why?
|
| Male | 6 | 2016 | 25399 | 0.140 |
Why?
|
| Narcotics | 1 | 2016 | 111 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 158 | 0.130 |
Why?
|
| Ankle Injuries | 1 | 2014 | 10 | 0.120 |
Why?
|
| Ilizarov Technique | 1 | 2014 | 1 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2016 | 187 | 0.120 |
Why?
|
| Fracture Healing | 1 | 2014 | 27 | 0.120 |
Why?
|
| Hypertrophy | 1 | 2014 | 50 | 0.120 |
Why?
|
| Fracture Fixation, Internal | 1 | 2014 | 40 | 0.120 |
Why?
|
| Injury Severity Score | 1 | 2014 | 159 | 0.120 |
Why?
|
| Prognosis | 2 | 2009 | 1954 | 0.110 |
Why?
|
| Forearm | 1 | 2013 | 32 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2014 | 106 | 0.110 |
Why?
|
| Femur | 1 | 2014 | 133 | 0.110 |
Why?
|
| Trauma Centers | 1 | 2014 | 193 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2016 | 2379 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 285 | 0.110 |
Why?
|
| Aged | 3 | 2013 | 9405 | 0.100 |
Why?
|
| Reoperation | 1 | 2014 | 454 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2005 | 201 | 0.100 |
Why?
|
| Biopsy | 1 | 2013 | 590 | 0.100 |
Why?
|
| Female | 6 | 2016 | 26635 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2014 | 6134 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 2922 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2190 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 164 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 181 | 0.080 |
Why?
|
| Gastrectomy | 1 | 2009 | 68 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 227 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 137 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2005 | 86 | 0.070 |
Why?
|
| Adolescent | 2 | 2016 | 6390 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 581 | 0.070 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2007 | 26 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2005 | 349 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1541 | 0.070 |
Why?
|
| Cadaver | 1 | 2006 | 97 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 738 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 978 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 219 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 17 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 24 | 0.060 |
Why?
|
| United States | 1 | 2016 | 4874 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2005 | 39 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2005 | 84 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2005 | 95 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2009 | 1262 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 172 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 144 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2004 | 353 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 3154 | 0.050 |
Why?
|
| Wrist Joint | 1 | 2021 | 9 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2021 | 44 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2016 | 168 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 97 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 240 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2005 | 96 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2005 | 176 | 0.030 |
Why?
|
| Middle Aged | 1 | 2009 | 12206 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 56 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 586 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 793 | 0.030 |
Why?
|
| Adult | 1 | 2009 | 13324 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2005 | 846 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2005 | 650 | 0.020 |
Why?
|
| Elasticity | 1 | 2007 | 20 | 0.020 |
Why?
|
| Insulin Antibodies | 1 | 2005 | 1 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 26 | 0.020 |
Why?
|
| Glutamate Decarboxylase | 1 | 2004 | 6 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2005 | 25 | 0.020 |
Why?
|
| Clone Cells | 1 | 2004 | 78 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 24 | 0.020 |
Why?
|
| Mice | 2 | 2005 | 5759 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 1185 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 223 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 221 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 222 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 688 | 0.010 |
Why?
|
| Animals | 2 | 2005 | 13246 | 0.010 |
Why?
|